In:
European Respiratory Journal, European Respiratory Society (ERS), Vol. 61, No. 3 ( 2023-03), p. 2201596-
Abstract:
Suboptimal exposure to antituberculosis (anti-TB) drugs has been associated with unfavourable treatment outcomes. We aimed to investigate estimates and determinants of first-line anti-TB drug pharmacokinetics in children and adolescents at a global level. Methods We systematically searched MEDLINE, Embase and Web of Science (1990–2021) for pharmacokinetic studies of first-line anti-TB drugs in children and adolescents. Individual patient data were obtained from authors of eligible studies. Summary estimates of total/extrapolated area under the plasma concentration–time curve from 0 to 24 h post-dose (AUC 0–24 ) and peak plasma concentration ( C max ) were assessed with random-effects models, normalised with current World Health Organization-recommended paediatric doses. Determinants of AUC 0–24 and C max were assessed with linear mixed-effects models. Results Of 55 eligible studies, individual patient data were available for 39 (71%), including 1628 participants from 12 countries. Geometric means of steady-state AUC 0–24 were summarised for isoniazid (18.7 (95% CI 15.5–22.6) h·mg·L −1 ), rifampicin (34.4 (95% CI 29.4–40.3) h·mg·L −1 ), pyrazinamide (375.0 (95% CI 339.9–413.7) h·mg·L −1 ) and ethambutol (8.0 (95% CI 6.4–10.0) h·mg·L −1 ). Our multivariate models indicated that younger age (especially 〈 2 years) and HIV-positive status were associated with lower AUC 0–24 for all first-line anti-TB drugs, while severe malnutrition was associated with lower AUC 0–24 for isoniazid and pyrazinamide. N -acetyltransferase 2 rapid acetylators had lower isoniazid AUC 0–24 and slow acetylators had higher isoniazid AUC 0–24 than intermediate acetylators. Determinants of C max were generally similar to those for AUC 0–24 . Conclusions This study provides the most comprehensive estimates of plasma exposures to first-line anti-TB drugs in children and adolescents. Key determinants of drug exposures were identified. These may be relevant for population-specific dose adjustment or individualised therapeutic drug monitoring.
Type of Medium:
Online Resource
ISSN:
0903-1936
,
1399-3003
DOI:
10.1183/13993003.01596-2022
DOI:
10.1183/13993003.01596-2022.Supp1
DOI:
10.1183/13993003.01596-2022.Shareable1
Language:
English
Publisher:
European Respiratory Society (ERS)
Publication Date:
2023
detail.hit.zdb_id:
2834928-3
detail.hit.zdb_id:
1499101-9
Bookmarklink